Patent SG-11201906404R-A (SG)
Title: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
Inventor: EVANS ELIZABETH
IPC: A61K39/395
Filed: 2018-03-14
Abstract: 1 CTRL 2 30 CTRL + ENT 3 30 aSEMA4D 30 1 aSEMA4D + ENT (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT O V SID o H 0101110E 1111101 Hs (10) International Publication Number WO 2018/175179 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/022414 (22) International Filing Date: 14 March 2018 (14.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/473,731 20 March 2017 (20.03.2017) US (71) Applicant: VACCINEX, INC. [US/US]; 1895 Mt. Hope Avenue, Rochester, New York 14620 (US). (72) Inventors: EVANS, Elizabeth; 41 Main Street, Bloom- field, New York 14469 (US). SMITH, Ernest S.; 67 Long- ton Place, West Henrietta, New York 14586 (US). ZAUD- ERER, Maurice; 44 Woodland Road, Pittsford, New York 14534 (US). (74) Agent: HAANES, Elizabeth J.; FisherBroyles LLP, 945 East Paces Road NE, Suite 2000, Atlanta, Georgia 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT FIGURE 1 Experimental Design trot 1g; 10mg/kg, ip, weary15; starting on day 2 500,000 Colon26 ENT: 20 mg/kg cells 3x/wk X6, starting at TV - 300 mm 3 4 , 4 , 4 , r 21 28 60 Caliper measurements, biweekly up to 60 days Grp N= Description (57) : This disclosure provides a method for inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising administering to the subject a combination therapy comprising an effective amount of an isolated antibody or antigen-bind- ing fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an epigenetic modulating agent, e.g., a histone deacetylase (HDAC) inhibitor (HDACi) a DNA methyltransferase (DNMT) inhibitor (DNMTi), or any combination thereof. The disclosure further provides a pharmaceutical composition comprising the combination therapy. [Continued on next page] WO 2018/175179 Al IMEDIM01101 DIONE1013010M1111111111111101111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))